Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resista... ( -- Lead NNRTI RDEA806 to begin Phase ...)

HOME >> BIOLOGY >> TECHNOLOGY

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

Date:4/14/2008

-- Lead NNRTI RDEA806 to begin Phase 2b trial in the second quarter of 2008

MONTREAL and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data was presented on the Company's next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds demonstrating potent activity against the human-immunodeficiency virus (HIV), including NNRTI- resistant strains, with the potential for improved performance over current NNRTIs.

The data were presented at the 21st International Conference on Antiviral Research (ICAR) in Montreal, Quebec, Canada.

The compounds in this series are potent against both wild-type and the most common NNRTI-resistant viruses and are more active than efavirenz (Sustiva(R), BMS) and nevirapine (Viramune(R), Boehringer-Ingelheim) against a broad panel of NNRTI-resistant clinical isolates.

"Safer, better tolerated NNRTIs that also work against viruses resistant to the most widely used NNRTIs, are needed to expand the armamentarium," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Our lead NNRTI, RDEA806, has shown the potential to match this profile and we are preparing to progress it into a Phase 2b trial later this quarter. An important part of our business strategy is to progress an additional next generation NNRTI, from the structurally novel series presented today, into Phase 1 later this year."

The poster is available on the Company website (http://www.ardeabio.com) under the title, "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses."

About RDEA806 '/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference

Post Your Comments:

(Date:12/1/2009)... Dr. Kerry Solomon announce...nd has launched his redesigned website at www.DrK...onsulting Group. Dr. Solomon is a proven LASIK, l...een professionally recognized for his substantial ...ry. He is a member of Trusted LASIK Surgeons, whi...

(Date:12/1/2009)..., , NEW YORK, Dec. 1 R...ch report is available in its catalogue: ,, C....reportlinker.com/p0164494/Chromium---Global-Marke... is primarily influenced by stainless steel, while...rkets is also important for growth of chromium met...

(Date:12/1/2009)..., , NEW YORK, Dec. 1 R...ch report is available in its catalogue: ,, Em...Market dynamics and the changing healthcare and re...er.com/p0165658/Emerging-Clinical-Trial-Locations-...healthcare-and-regulatory-environment.html ,, ...

(Date:12/1/2009)..., , CAMBRIDGE, Mass., Dec. 1 /PRNewsw...biology industry and to promote its potential, a g...rmation of the Synthetic Biology Industry Associat.... The goal of the association is to provide a foru...uss the new industry, address its opportunities an...

Breaking Biology Technology:Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6 Reportlinker Adds Chromium - Global Market Trends 2 Reportlinker Adds Chromium - Global Market Trends 3 Reportlinker Adds Chromium - Global Market Trends 4 Reportlinker Adds Chromium - Global Market Trends 5 Reportlinker Adds Chromium - Global Market Trends 6 Reportlinker Adds Chromium - Global Market Trends 7 Reportlinker Adds Chromium - Global Market Trends 8 Reportlinker Adds Chromium - Global Market Trends 9 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8 Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2

[0] Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com [0] Reportlinker Adds Chromium - Global Market Trends [0] Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment [0] Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology

...t. 8 Wyeth Pharmaceuticals, a,division of Wyeth (...ts have,begun for XYNTHA(TM) Antihemophilic Factor...ant factor VIII product for both the,control and p...laxis in,patients with hemophilia A, a rare, inher... using state-of-the-art manufacturing and,purifica...

...wswire-FirstCall/ - Oncolytics Biotech Inc.,("Onco...at that it has,started patient enrolment in a Phas...n of REOLYSIN(R) in combination with paclitaxel an...eck cancers. The Principal,Investigator is Dr. Mon...CTRC) at The University of Texas Health Science Ce...

...rescriber, Software Simplifies Medicare - For Free...,announced the latest release of their PlanPrescri...o longer need to worry about whether they are,gett...ns. PlanPrescriber,the brainchild of MIT Professor... advice to help seniors quickly find their best Me...

Other Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2 New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3 New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4 New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5 Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2 Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3 On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2

New Recombinant XYNTHA Now Available for Patients with Hemophilia A Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin On-Line Medicare Advisor Saves Seniors Time, Hassle and Money

(Date:12/1/2009)...ased to announce the publication of results from i...acy and tolerability of its novel, intranasal drug...ic rhinosinusitis with nasal polyps in Rhinology ...ropean Rhinologic Societies. , Chronic rhinosin... can significantly reduce a patient,s quality of l...

(Date:12/1/2009)...sity cancer researchers have developed a tumor-at...d blocks the growth of new tumor blood vessels. ,...ll cancer cells oncolytic viruses might be more ...also carry a gene for a protein that inhibits bloo...tin, is normally produced in the brain. In this st...

(Date:12/1/2009)...tacks by sharks can be solved with a new technique...they put on their victims, according to a Universi...a method analogous to analyzing human fingerprints... comparing shark bites to the jaws and teeth of th...r of the International Shark Attack File, which is...

Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2 Tumor-attacking virus strikes with 'one-two punch' 2 New forensic technique gives clues about sharks from bite damage 2 New forensic technique gives clues about sharks from bite damage 3 Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 50666 1 Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 50666 2 Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 1 Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 2 Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 3 Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 4 If 2 Painkillers Are Banned What Next 3F 50662 1 If 2 Painkillers Are Banned What Next 3F 50662 2 If 2 Painkillers Are Banned What Next 3F 50662 3 If 2 Painkillers Are Banned What Next 3F 50662 4

[0] New data on highly effective treatment for chronic rhinosinusitis with nasal polyps [0] Tumor-attacking virus strikes with 'one-two punch'[0] New forensic technique gives clues about sharks from bite damage

...entists working in an ice-free region of Antarctic...e form of fossilized plants and insects--on the in...atures began a relentless drop millions of years a... degrees Celsius, over a relatively brief period o...rced the extinction of tundra plants and insects a...

... traditionally focused on protecting individual sp...ring, however, that preserving the benefits that w...ally and environmentally valuable. At the Annual M... ecologists will explore the application of ecosys...tem services are the benefits that humans reap fro...

... professor and Georgia Research Alliance Eminent S...eorgia, has been awarded $9.2 million as part of a...e of General Medical Sciences, part of the Nationa...rtered in the department of biochemistry and molec...ings of the early steps that stem cells take in be...

Other Biology News:Antarctic fossils paint a picture of a much warmer continent 2 Antarctic fossils paint a picture of a much warmer continent 3 Antarctic fossils paint a picture of a much warmer continent 4 Antarctic fossils paint a picture of a much warmer continent 5 Evaluating ecosystem services 2 Evaluating ecosystem services 3 UGA researchers win $9.2 million stem cell grant from NIH 2

Antarctic fossils paint a picture of a much warmer continent Evaluating ecosystem services UGA researchers win $9.2 million stem cell grant from NIH

...vides complete components including positive and n...DNA fragmentation in cultured cells and tissue sec...optotic cells. Internucleosomal DNA fragmentatio...BLs ApoDIRECT In Situ DNA Fragmentation Assay Kit ...

... , Removes >99% detergent , Very selective, virtu...ple, just pipette, centrifuge and discard pellet ,...hydrophobic chromatography , Detergents can often ...s a simple and fast method to remove SDS and non-i...

EXTRACTI-GEL D from Pierce Biotechnology, Inc.

Solvent-Detergent Removal Resin from Sigma-Aldrich

Biology Products:

ApoDIRECT DNA Fragmentation Assay Kit from MBL International SurfactAway SDS from Biotech Support Group EXTRACTI-GEL D from Pierce Biotechnology, Inc.Solvent-Detergent Removal Resin from Sigma-Aldrich

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resista...( -- Lead NNRTI RDEA806 to begin Phase ...)